AP NEWS

Primary Hyperoxaluria (PH) Market Insights, Epidemiology and Market Forecast, 2027 - ResearchAndMarkets.com

June 14, 2018

DUBLIN--(BUSINESS WIRE)--Jun 14, 2018--The “Primary Hyperoxaluria (PH) - Market Insights, Epidemiology and Market Forecast-2027” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Primary Hyperoxaluria (PH) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Primary Hyperoxaluria (PH) - Disease Understanding and Treatment Algorithm

The Primary Hyperoxaluria (PH) market report gives the thorough understanding of the Primary Hyperoxaluria (PH) by including details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Primary Hyperoxaluria (PH) in the US, EU5, and Japan.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, Type specific diagnosed prevalent cases (PH Type 1, 2, 3 & unclassified) and Age-Specific diagnosed prevalent cases) scenario of Primary Hyperoxaluria (PH) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to this research, the total number of diagnosed prevalent population of Primary Hyperoxaluria (PH) was found to be 3,714, in the year 2016.

Key Topics Covered:

1. Key Insights

2. Primary Hyperoxaluria Market Overview at a Glance

2.1. Market Share (%) Distribution of Primary Hyperoxaluria in 2017

2.2. Market Share (%) Distribution of Primary Hyperoxaluria in 2027

3. Disease Background and Overview: Primary Hyperoxaluria (PH)

3.1. Introduction

3.2. Symptoms

3.3. Genetic basis of Primary Hyperoxaluria

3.4. Classification

3.5. Etiology

3.6. Pathophysiology

3.7. Diagnosis

3.8. Management

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Forecast Methodology

5. 7MM Total Diagnosed Prevalent Patient Population of Primary Hyperoxaluria

6. Country Wise-Epidemiology of Primary Hyperoxaluria

6.1. United States

6.2. EU5 Countries

7. Treatment Algorithm, Current Treatment, and Medical Practices

8. Unmet Needs

9. Emerging Drugs

9.1. Key Cross Competition

9.2. Oxabact: OxThera

9.3. Lumasiran: Alnylam Pharmaceuticals

9.4. ALLN-177: Allena Pharmaceuticals

10. Primary Hyperoxaluria: 7 Major Market Analysis

11. The United States Market Outlook

12. EU-5 Countries: Market Outlook

13. Market Drivers

14. Market Barriers

15. Appendix

16. Capabilities

Companies Mentioned

OxThera Alnylam Pharmaceuticals Allena Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/6z9xb5/primary?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180614006203/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/14/2018 04:13 PM/DISC: 06/14/2018 04:13 PM

http://www.businesswire.com/news/home/20180614006203/en

AP RADIO
Update hourly